February 12th 2024
The NCCN has published the first set of treatment recommendations for neuroblastoma.
Preferentially expressed antigen in melanoma has emerged as a target for treatment development in multiple solid tumors.
February 11th 2024
Experts discuss treatment in newly diagnosed multiple myeloma and the role of CAR T-cell therapies and bispecifics in relapsed/refractory disease.
February 9th 2024
Trabectedin did not offer a survival benefit vs chemotherapy in recurrent ovarian cancer with BRCA-mutated and/or BRCAness phenotype.
February 7th 2024
The NCCN Breast Cancer Panel has included goserelin at 2 dosing schedules as a method for ovarian function suppression in their updated guidelines.
The University of Hawaii Cancer Center hopes to address treatment needs through its planned Early Phase Clinical Research Center.
February 6th 2024
Thomas J. Lynch Jr, MD, details how treatments are evolving for patients with EGFR-mutated advanced non–small cell lung cancer.
February 2nd 2024
Investigators have developed a machine learning algorithm that could eventually facilitate earlier cancer detection via smaller blood draws.
February 1st 2024
Expert oncologists in the field of breast cancer review data in HER2-positive early-stage and metastatic breast cancer.
January 31st 2024
A sBLA seeking the approval of D-VRd for transplant-eligible patients with newly diagnosed multiple myeloma was submitted to the FDA.
January 30th 2024
Phase 2 trial investigators hope denifanstat can be a key component in restoring sensitivity to HER2- positive metastatic breast cancer treatments.
January 27th 2024
Subcutaneous nivolumab coformulated with rHuPH20 demonstrated noninferiority of PK exposures vs intravenous nivolumab in metastatic ccRCC.
January 25th 2024
The FDA has called to add a class-wide boxed warning for CAR T-cell therapies to alert patients of the risk of developing secondary T-cell malignancies.
January 24th 2024
As the treatment paradigm in urothelial cancer expands to include agents directed at various targets, NECTIN-4 has emerged as a promising treatment target.
January 23rd 2024
Oncologists reviewed data from clinical trials in the field of melanoma that could add clarity to treatment standards and lead to improved patient care.
January 22nd 2024
Olverembatinib has been added to the NCCN's latest 2024 guidelines for management of chronic myeloid leukemia.
January 19th 2024
Tiragolumab plus atezolizumab and chemotherapy produced superior survival benefit vs chemotherapy for patients with esophageal squamous cell carcinoma.
Tampa General Hospital Cancer Institute has experienced much growth since its establishment, in terms of attracting talent and expanding their footprint.
January 17th 2024
Amit Mahipal, MD, discusses data on camrelizumab plus rivoceranib in advanced HCC and the phase 3 CARES-310 trial, which is currently enrolling patients.
January 16th 2024
GB2064 displayed efficacy with a generally acceptable tolerability profile in the treatment of patients with myelofibrosis.